In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK gets late-stage cancer/RA antibody from Genmab; transferred to Novartis

Executive Summary

Less than two weeks after acquiring antibody specialist Domantis, GlaxoSmithKline is again building up its large molecule pipeline by in-licensing exclusive worldwide rights to Danish firm Genmab AS's HuMax-CD20 (ofatumumab) fully human monoclonal antibody plus other anti-CD20 antibodies that Genmab may develop.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies